Biohaven (BHVN)

• Market cap: $1.42B
• 1 day: -7.32%
• 5 days: -3.20%
• 1 month: -11.22%
• 3 months: -20.94%
• 6 months: -62.83%
• Year to date: -62.63%
• 1 year: -63.29%
• 5 years: 95.10%
• 10 years: 95.10%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

304% more call options, than puts

Call options by funds: $30.7M | Put options by funds: $7.59M

24% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 37

24% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 76

2% more funds holding

Funds holding: 253 [Q4 2024] → 259 (+6) [Q1 2025]

3.46% less ownership

Funds ownership: 91.26% [Q4 2024] → 87.8% (-3.46%) [Q1 2025]

22% less funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]

37% less capital invested

Capital invested by funds: $3.48B [Q4 2024] → $2.2B (-$1.28B) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 51% upside
• Avg. target: $44 218% upside
• High target: $57 309% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

JP Morgan Tessa Romero	295% upside $55	Overweight Maintained	18 Jun 2025
RBC Capital Leonid Timashev	51% upside $21	Sector Perform Downgraded	19 May 2025
Baird Brian Skorney	309% upside $57	Outperform Maintained	28 Apr 2025